Approach to the patient with advanced differentiated thyroid cancer

European Journal of Endocrinology

Volumn 166, Issue 1, 2012, Pages 5-11

  Schlumberger, M ^a   Sherman, S I ^b  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AXITINIB; B RAF KINASE; CISPLATIN; DOXORUBICIN; FIBROBLAST GROWTH FACTOR; FLUORODEOXYGLUCOSE F 18; IODINE; LENVATINIB; MOTESANIB; PAZOPANIB; PLACEBO; PLATELET DERIVED GROWTH FACTOR; PROTEIN P53; PROTEIN RET; RAS PROTEIN; SELUMETINIB; SORAFENIB; SUNITINIB; VANDETANIB; VASCULOTROPIN; VASCULOTROPIN RECEPTOR; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; VEMURAFENIB;

ADVANCED CANCER; AGE; ANAPLASTIC CARCINOMA; BRAF GENE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; CARCINOGENESIS; COMPUTER ASSISTED TOMOGRAPHY; CUTANEOUS SQUAMOUS CELL CANCER; DEVELOPMENTAL GENE; DIFFERENTIATED THYROID CANCER; DISEASE ACTIVITY; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; FOLLICULAR CARCINOMA; GENE TARGETING; HEALTH STATUS; HUMAN; KERATOACANTHOMA; METASTASIS POTENTIAL; MONOTHERAPY; NUCLEAR MAGNETIC RESONANCE IMAGING; ONCOCYTOMA; ONCOGENE RAS; PAPILLARY CARCINOMA; PAX8 GENE; PIK3CA GENE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; RET GENE; REVIEW; SQUAMOUS CELL CARCINOMA; SYSTEMATIC REVIEW; TP53 GENE; TREATMENT DURATION; TREATMENT RESPONSE;

CLINICAL TRIALS AS TOPIC; HUMANS; IODINE RADIOISOTOPES; THYROID NEOPLASMS; THYROXINE;

EID: 84055184770     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-11-0631     Document Type: Review

References (46)

1. Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, Mazzaferri EL, McIver B, Pacini F, Schlumberger M, Sherman SI, Steward DL & Tuttle RM. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009 19 1167-1214. (doi:10.1089/thy.2009.0110)
2. Baudin E & Schlumberger M. New therapeutic approaches for metastatic thyroid carcinoma. Lancet Oncology 2007 8 148-156. (doi:10.1016/S1470-2045(07) 70034-7)
3. Schlumberger M & Sherman SI. Clinical trials for progressive differentiated thyroid cancer: patient selection, study design, and recent advances. Thyroid 2009 19 1393-1400. (doi:10.1089/thy. 2009.1603)
4. Durante C, Haddy N, Baudin E, Leboulleux S, Hartl D, Travagli JP, Caillou B, Ricard M, Lumbroso JD, De Vathaire F & Schlumberger M. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. Journal of Clinical Endocrinology and Metabolism 2006 91 2892-2899. (doi:10.1210/jc.2005-2838)
5. Jonklaas J, Sarlis NJ, Litofsky D, Ain KB, Bigos ST, Brierley JD, Cooper DS, Haugen BR, Ladenson PW, Magner J, Robbins J, Ross DS, Skarulis M, Maxon HR & Sherman SI. Outcomes of patients with differentiated thyroid carcinoma following initial therapy. Thyroid 2006 16 1229-1242. (doi:10.1089/thy.2006. 16.1229)
6. Biondi B, Filetti S & Schlumberger M. Thyroid-hormone therapy and thyroid cancer: a reassessment. Nature Clinical Practice. Endocrinology and Metabolism 2005 1 32-40. (doi:10.1038/ncpendmet0020)
7. Schwartz DL, Lobo MJ, Ang KK, Morrison WH, Rosenthal DI, Ahamad A, Evans DB, Clayman G, Sherman SI & Garden AS. Postoperative external beam radiotherapy for differentiated thyroid cancer: outcomes and morbidity with conformal treatment. International Journal of Radiation Oncology, Biology, Physics 2009 74 1083-1091. (doi:10.1016/j.ijrobp.2008.09.023)
8. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D & Verweij J. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). European Journal of Cancer 2009 45 228-247. (doi:10.1016/j.ejca.2008.10.026)
9. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC & Gwyther SG. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. Journal of the National Cancer Institute 2000 92 205-216. (doi:10.1093/jnci/92.3.205)
10. Shimaoka K, Schoenfeld DA, DeWys WD, Creech RH & DeConti R. A randomized trial of doxorubicin versus doxorubicin plus cisplatin in patients with advanced thyroid carcinoma. Cancer 1985 56 2155-2160. (doi:10.1002/1097- 0142(19851101) 56:9〈2155::AID-CNCR2820560903〉3.0.CO;2-E)
11. Williams SD, Birch R & Einhorn LH. Phase II evaluation of doxorubicin plus cisplatin in advanced thyroid cancer: a Southeastern Cancer Study Group Trial. Cancer Treatment Reports 1986 70 405-407. (Pubitemid 16130224)
12. Sherman SI. Cytotoxic chemotherapy for differentiated thyroid carcinoma. Clinical Oncology 2010 22 464-468. (doi:10.1016/j. clon.2010.03.014)
13. Fagin JA. How thyroid tumors start and why it matters: kinase mutants as targets for solid cancer pharmacotherapy. Journal of Endocrinology 2004 183 249-256. (doi:10.1677/joe.1.05895)
14. Kondo T, Ezzat S & Asa SL. Pathogenetic mechanisms in thyroid follicular-cell neoplasia. Nature Reviews. Cancer 2006 6 292-306. (doi:10.1038/nrc1836)
15. Volante M, Rapa I, Gandhi M, Bussolati G, Giachino D, Papotti M & Nikiforov YE. RAS mutations are the predominant molecular alteration in poorly differentiated thyroid carcinomas and bear prognostic impact. Journal of Clinical Endocrinology and Metabolism 2009 94 4735-4741. (doi:10.1210/jc.2009- 1233)
16. Volante M, Collini P, Nikiforov YE, Sakamoto A, Kakudo K, Katoh R, Lloyd RV, LiVolsi VA, Papotti M, Sobrinho-Simoes M, Bussolati G & Rosai J. Poorly differentiated thyroid carcinoma: the Turin proposal for the use of uniform diagnostic criteria and an algorithmic diagnostic approach. American Journal of Surgical Pathology 2007 31 1256-1264. (doi:10.1097/PAS.0b013e31 80309e6a)
17. Ringel MD, Hayre N, Saito J, Saunier B, Schuppert F, Burch H, Bernet V, Burman KD, Kohn LD & Saji M. Overexpression and overactivation of Akt in thyroid carcinoma. Cancer Research 2001 61 6105-6111. (Pubitemid 32762546)
18. Bruni P, Boccia A, Baldassarre G, Trapasso F, Santoro M, Chiappetta G, Fusco A & Viglietto G. PTEN expression is reduced in a subset of sporadic thyroid carcinomas: evidence that PTEN-growth suppressing activity in thyroid cancer cells mediated by p27kip1. Oncogene 2000 19 3146-3155. (doi:10.1038/sj.onc. 1203633)
19. Wu G, Mambo E, Guo Z, Hu S, Huang X, Gollin SM, Trink B, Ladenson PW, Sidransky D & Xing M. Uncommon mutation, but common amplifications, of the PIK3CA gene in thyroid tumors. Journal of Clinical Endocrinology and Metabolism 2005 90 4688-4693. (doi:10.1210/jc.2004-2281)
20. Santarpia L, El-Naggar AK, Cote GJ, Myers JN & Sherman SI. PI3K/Akt and Ras/Raf-MAPK pathway mutations in anaplastic thyroid cancer. Journal of Clinical Endocrinology and Metabolism 2008 93 278-284. (doi:10.1210/jc.2007- 1076)
21. Bunone G, Vigneri P, Mariani L, Butó S, Collini P, Pilotti S, Pierotti MA & Bongarzone I. Expression of angiogenesis stimulators and inhibitors in human thyroid tumors and correlation with clinical pathological features. American Journal of Pathology 1999 155 1967-1976. (doi:10.1016/S0002- 9440(10)65515-0)
22. Klein M, Vignaud JM, Hennequin V, Toussaint B, Bresler L, Plénat F, Leclère J, Duprez A & Weryha G. Increased expression of the vascular endothelial growth factor is a pejorative prognosis marker in papillary thyroid carcinoma. Journal of Clinical Endocrinology and Metabolism 2001 86 656-658. (doi:10.1210/jc.86.2.656)
23. Soh EY, Eigelberger MS, Kim KJ, Wong MG, Young DM, Clark OH & Duh QY. Neutralizing vascular endothelial growth factor activity inhibits thyroid cancer growth in vivo. Surgery 2000 128 1059-1065; (discussion 1065-6). (doi:10.1067/msy.2000. 110430)
24. Tuttle RM, Ball DW, Byrd D, Dilawari RA, Doherty GM, Duh QY, Ehya H, Farrar WB, Haddad RI, Kandeel F, Kloos RT, Kopp P, Lamonica DM, Loree TR, Lydiatt WM, McCaffrey JC, Olson JA Jr, Parks L, Ridge JA, Shah JP, Sherman SI, Sturgeon C, Waguespack SG, Wang TN & Wirth LJ. Thyroid carcinoma. Journal of the National Comprehensive Cancer Network 2010 8 1228-1274.
25. Sherman SI, Wirth LJ, Droz JP, Hofmann M, Bastholt L, Martins RG, Licitra L, Eschenberg MJ, Sun YN, Juan T, Stepan DE & Schlumberger MJ. Motesanib diphosphate in progressive differentiated thyroid cancer. New England Journal of Medicine 2008 359 31-42. (doi:10.1056/NEJMoa075853)
26. Gupta-Abramson V, Troxel AB, Nellore A, Puttaswamy K, Redlinger M, Ransone K, Mandel SJ, Flaherty KT, Loevner LA, O'Dwyer PJ & Brose MS. Phase II trial of sorafenib in advanced thyroid cancer. Journal of Clinical Oncology 2008 26 4714-4719. (doi:10.1200/JCO.2008.16.3279)
27. Kloos RT, Ringel MD, Knopp MV, Hall NC, King M, Stevens R, Liang J, Wakely PE Jr, Vasko VV, Saji M, Rittenberry J, Wei L, Arbogast D, Collamore M, Wright JJ, Grever M & Shah MH. Phase II trial of sorafenib in metastatic thyroid cancer. Journal of Clinical Oncology 2009 27 1675-1684. (doi:10.1200/JCO.2008.18. 2717)
28. Hoftijzer H, Heemstra KA, Morreau H, Stokkel MP, Corssmit EP, Gelderblom H, Weijers K, Pereira AM, Huijberts M, Kapiteijn E, Romijn JA & Smit JW. Beneficial effects of sorafenib on tumor progression, but not on radioiodine uptake, in patients with differentiated thyroid carcinoma. European Journal of Endocrinology 2009 161 923-931. (doi:10.1530/EJE-09-0702)
29. Ahmed M, Barbachano Y, Riddell AM, Hickey J, Newbold KL, Viros A, Harrington KJ, Marais R & Nutting CM. Analysis of the efficacy and toxicity of sorafenib in thyroid cancer - a phase II study in a UK based population. European Journal of Endocrinology 2011 165 315-322. (doi:10.1530/EJE-11-0129)
30. Waguespack SG, Sherman SI, Williams MD, Clayman GL & Herzog CE. The successful use of sorafenib to treat pediatric papillary thyroid carcinoma. Thyroid 2009 19 407-412. (doi:10. 1089/thy.2008.0429)
31. Leboulleux S, Bastholt L, Krause TM, De La Fouchardiere C, Tennvall Jan, Awada A, Gomez JM, Tisseron Carrasco A, Licour M & Schlumberger Leboulleux MJ. Vandetanib in locally advanced or metastatic differentiated thyroid cancer (papillary; follicular; DTC): a randomized, double-blind phase II trial. 14th International Thyroid Congress (Paris, 2010).
32. Carr LL, Mankoff DA, Goulart BH, Eaton KD, Capell PT, Kell EM, Bauman JE & Martins RG. Phase II study of daily sunitinib in FDG-PET-positive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation. Clinical Cancer Research 2010 16 5260-5268. (doi:10.1158/1078-0432.CCR-10-0994)
33. Cohen EE, Needles BM, Cullen KJ, Wong SJ, Wade JL III, Ivy SP, Villaflor VM, Seiwert TY, Nichols K & Vokes EE. Phase 2 study of sunitinib in refractory thyroid cancer. Journal of Clinical Oncology 2008 26 6025.
34. Cohen EE, Rosen LS, Vokes EE, Kies MS, Forastiere AA,Worden FP, Kane MA, Sherman E, Kim S, Bycott P, Tortorici M, Shalinsky DR, Liau KF & Cohen RB. Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study. Journal of Clinical Oncology 2008 26 4708-4713. (doi:10.1200/JCO.2007.15.9566)
35. Bible KC, Suman VJ, Molina JR, Smallridge RC, Maples WJ, Menefee ME, Rubin J, Sideras K, Morris JC III, McIver B, Burton JK, Webster KP, Bieber C, Traynor AM, Flynn PJ, Goh BC, Tang H, Ivy SP & Erlichman C. Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study. Lancet Oncology 2010 11 962-972. (doi:10.1016/S1470-2045(10)70203-5)
36. Nemunaitis JJ, Senzer NN, Kurzrock R, Ng CS, Das A, Atienza RS, Zang EA, Jansen M, Ashworth S & Hong DS. Phase I dose-escalation study of E7080, a multikinase inhibitor, in patients with advanced solid tumors. Journal of Clinical Oncology 2008 26 14583. (doi:10.1200/JCO.2007.15.2843)
37. Sherman SI, Jarzab B, Cabanillas ME, Licitra LF, Pacini F, Martins R, Robinson B, Ball D, McCaffrey J, Shah MH, Bodenner D, Allison R, Newbold K, Elisei R, O'Brien JP & Schlumberger M. A phase II trial of the multi-targeted kinase inhibitor, Lenvatinib (E7080), in advanced radioiodine-refractory differentiated thyroid cancer (DTC). Journal of Clinical Oncology (Meeting Abstracts) 2011 29 15-suppl 5503.
38. Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA, O'Dwyer PJ, Lee RJ, Grippo JF, Nolop K & Chapman PB. Inhibition of mutated, activated BRAF in metastatic melanoma. New England Journal of Medicine 2010 363 809-819. (doi:10.1056/NEJMoa1002011)
39. Schwartz GK, Robertson S, Shen A, Wang E, Pace L, Dials H, Mendelson D, Shannon P & Gordon M. A phase I study of XL281, a selective oral RAF kinase inhibitor, in patients (Pts) with advanced solid tumors. Journal of Clinical Oncology 2009 27 3513. (doi:10. 1200/JCO.2008.20.3745)
40. Lucas AS, Cohen EE, Cohen RB, Krzyzanowska MK, Chung CH, Murphy BA, Tanvetyanon T, Gilbert J, Moore DT & Hayes DN. Phase II study and tissue correlative studies of AZD6244 (ARRY-142886) in iodine-131 refractory papillary thyroid carcinoma (IRPTC) and papillary thyroid carcinoma (PTC) with follicular elements. Journal of Clinical Oncology 2010 28 5536.
41. Leboeuf R, Baumgartner JE, Benezra M, Malaguarnera R, Solit D, Pratilas CA, Rosen N, Knauf JA & Fagin JA. BRAFV600E mutation is associated with preferential sensitivity to mitogen-activated protein kinase kinase inhibition in thyroid cancer cell lines. Journal of Clinical Endocrinology and Metabolism 2008 93 2194-2201. (doi:10.1210/jc.2007-2825)
42. Abdulrahman RM, Verloop H, Hoftijzer H, Verburg E, Hovens GC, Corssmit EP, Reiners C, Gelderblom H, Pereira AM, Kapiteijn E, Romijn JA, Visser TJ & Smit JW. Sorafenib-induced hypothyroidism is associated with increased type 3 deiodination. Journal of Clinical Endocrinology and Metabolism 2010 95 3758-3762. (doi:10. 1210/jc.2009-2507)
43. Robert C, Arnault JP & Mateus C. RAF inhibition and induction of cutaneous squamous cell carcinoma. Current Opinion in Oncology 2011 23 177-182. (doi:10.1097/CCO.0b013e3283436e8c)
44. Poulikakos PI, Zhang C, Bollag G, Shokat KM & Rosen N. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature 2010 464 427-430. (doi:10.1038/nature08902)
45. Tsimberidou AM, Vaklavas C, Wen S, Hong D, Wheler J, Ng C, Naing A, Tse S, Busaidy N, Markman M, Sherman SI & Kurzrock R. Phase I clinical trials in 56 patients with thyroid cancer: the M.D. Anderson Cancer Center experience. Journal of Clinical Endocrinology and Metabolism 2009 94 4423-4432. (doi:10.1210/jc.2009-0743)
46. Hong DS, Cabanillas ME, Wheler J, Naing A, Tsimberidou AM, Ye L, Waguespack SG, Hernandez M, El Naggar AK, Bidyasar S, Wright J, Sherman SI & Kurzrock R. Inhibition of the Ras/Raf/MEK/ERK and RET kinase pathways with the combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in medullary and differentiated thyroid malignancies. Journal of Clinical Endocrinology and Metabolism 2011 96 997-1005. (doi:10.1210/jc.2010-1899)